Back to search results

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

This study, called COMPASS, is for men with prostate cancer who are already participating in the SYNERGY-201 clinical trial. SYNERGY-201 is testing a combination of SX-682 and enzalutamide. The COMPASS study aims to understand if a specific marker called CXCR2 (C-X-C chemokine receptor type 2) can predict who will benefit most from the SX-682 and enzalutamide treatment. Researchers will measure CXCR2 in your tumor and immune cells to see if its levels are linked to how well you respond to treatment after 6 months. This is an observational study, meaning you won't receive new treatments, but researchers will collect information from you. The study plans to enroll 48 participants, but its current status is unclear.

Study design
This is an observational study planning to enroll 48 participants. It is a companion study to the SYNERGY-201 clinical trial.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure outcomes at 6 months from the start of your treatment in the SYNERGY-201 trial.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07050433

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

Recruiting
Not specifiedAges 18+Observational
Duke University
~48 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:CXCR2 as a biomarker

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with Tumor CXCR2 biomarker expression associated with clinical benefit (CB)
Measured over 6 months from Cycle 1 Day 1 (each cycle is 21 days)
+1 more outcome measured

Conditions

Prostate Cancer

Explore related trials

Prostate Carcinoma

Where it's being run

4 sites across 4 states
California1
Michigan1
North Carolina1
Wisconsin1

Study leadership

  • Andrew Armstrong, MD · PRINCIPAL_INVESTIGATOR · Duke University

Who to contact

Kellie Shobe, MS, BSN, RN
[email protected]
919-684-8299
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Willing and able to provide written informed consent for this study and HIPAA authorization for the release of personal health information.
Age \>18
Participating in the SYNGERY-201 clinical trial.

Exclusion

History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study
History or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the subject's participation for the full duration of the study
History or current evidence of any condition, therapy, or laboratory abnormality that is not in the best interest of the subject to participate (in the opinion of the treating investigator)

What this trial measures

  • Number of participants with Tumor CXCR2 biomarker expression associated with clinical benefit (CB)6 months from Cycle 1 Day 1 (each cycle is 21 days)

    The association between tumor CXCR2 (dichotomized as absent or present CXCR2 levels in tumor at baseline as compared to negative control tissue) and CB will be measured using an odds ratio with 95% CI.

  • Number of participants with Immune cell CXCR2 biomarker expression associated with clinical benefit (CB)6 months from Cycle 1 Day 1 (each cycle is 21 days)

    The association between immune cell CXCR2 (dichotomized as present or absent in any myeloid immune cell subset) and CB will be measured using an odds ratio with 95% CI.